Themen:
News
Insights
10 July 2025
We have been appointed as joint corporate broker to HUTCHMED (China) Limited, a c.£2.0bn market cap business headquartered in Hong Kong and listed on AIM, Nasdaq and HKEX.
HUTCHMED is an innovative biopharma company focused on the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases. It generated $630m of revenue in 2024, and is one of the largest companies trading on AIM.